Cell Therapy Bioprocessing Market is anticipated to accumulate USD 30,052.6 million by 2028, says The Insight Partners

According to The Insight Partners' research, the cell therapy bioprocessing market was assessed at US$ 11,192.50 million in 2020 and is projected to be worth US$ 30,052.61 million by 2028, growing at a 13.5% CAGR between 2021 and 2028. Increasing investments for cell and gene therapy manufacturing and growing approvals for cell therapies are expected to be the prime drivers for the cell therapy bioprocessing market.

Cell and gene therapy is still in an early stage of development in the biotechnology sector. Despite being a niche domain of the biotechnology sector, cell and gene therapy has paved investments by contract development and manufacturing organizations (CDMO)/contract manufacturing organizations (CMO). Companies are investing in enhancing their manufacturing capabilities and offering world-class therapies to treat chronic conditions. In February 2020, Catalent, Inc. and MaSTherCell Global, Inc. signed an agreement in which Catalent, Inc. agreed to acquire MaSTherCell Global, Inc. for an amount of US$ 135 million.
According to the Alliance for Regenerative Medicine (ARM), investments in cell and gene therapy doubled in 2020 compared to 2019 and were considerably higher than in 2018. Thus, owing to the heavy investments, the market is expected to flourish in the coming years.

Get Sample PDF Copy of Cell Therapy Bioprocessing Market Size, Share, Growth- COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPRE00021550/?utm_source=OpenPR&utm_medium=10590

Leading players profiled in the cell therapy bioprocessing market report are Fresenius Kabi AG, Asahi Kasei Corporation, Sartorius AG, Merck KGaA, Thermo Fisher Scientific Inc, Corning Incorporated, Cytiva (GE Healthcare), Lonza, Repligen, and Catalent Inc.

Based on end user, the cell therapy bioprocessing market is segmented into hospitals and clinics, diagnostic centers, regenerative medicine centers, and academic and research institutes. The academic and research institute segment held the largest share of the market in 2020. The segment is estimated to register the highest CAGR of 14.1% in the market during the forecast period. It was valued at US$ 4,331.72 million in 2020 and is projected to reach US$ 12,141.53 million by 2028.

From the regional frame of reference, North America held a significant share in the cell therapy bioprocessing market in 2020. The regional market was assessed at US$ 5,031.03 million in 2020 and is slated to amass US$ 13,700.98 million by 2028, growing at a CAGR 13.7% during the forecast period. Meanwhile, APAC is predicted to register a stellar growth rate of 14.0% over the analysis period to garner US$ 5,872.28 million by 2028.

Avail Lucrative DISCOUNTS on "Cell Therapy Bioprocessing Market" Research Study: https://www.theinsightpartners.com/discount/TIPRE00021550/?utm_source=OpenPR&utm_medium=10590

Cell therapy involves the production of cartilage repair products, tissue-engineered skin, personalized medicines, and cellular immunotherapy to treat chronic diseases. The increasing need to treat chronic diseases has pushed the research and development activities resulting in growing cell therapy production and product approvals. Growing product developments have resulted in various product approvals that reflect the increase in cell therapies. Therefore, it is expected that the growing approvals for cell therapies are enormously increasing the cell therapy bioprocessing, which, in turn, is likely to drive the market's growth over the coming years.
On the other hand, cell therapy bioprocessing challenges hinder cell therapy bioprocessing augmentation.

Based on technology, the cell therapy bioprocessing market is divided into a bioreactor, lyophilization, electrospinning, control-flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. Of these, the bioreactor segment held 31.47% of the market share in 2020. The segment was assessed at US$ 3,521.94 million in 2020 and is projected to reach US$ 9,977.79 million by 2028, growing at a 14.2% CAGR during the forecast period.

As per cell type, the market is divided into stem cells, immune cells, human embryonic stem cells, pluripotent stem cells, and hematopoietic stem cells. Of these, the stem cell segment registered 48.53% of the market share in 2020. The segment was evaluated at US$ 5,431.23 million in 2020 and is slated to amass US$ 15,171.69 million by 2028, expanding at a 14% CAGR between 2021 and 2028.

Moving on to indication, the cell therapy bioprocessing market is divided into cardiovascular disease (CVD), oncology, wound healing, orthopedic, and others. Among these, the oncology segment accounted for 37.11% of the market share in 2020. The segment was evaluated at US$ 4,154.07 million in 2020 and is slated to garner US$ 11,530.16 million by 2028, augmenting at a 13.9% CAGR between 2021 and 2028.

Directly Purchase Premium Copy of cell therapy bioprocessing Market Growth Report at: https://www.theinsightpartners.com/buy/TIPRE00021550/?utm_source=OpenPR&utm_medium=10590

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.